WVE vs. PTCT, ZLAB, ACLX, RARE, RNA, AKRO, MRUS, OGN, MOR, and SWTX
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include PTC Therapeutics (PTCT), Zai Lab (ZLAB), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), Akero Therapeutics (AKRO), Merus (MRUS), Organon & Co. (OGN), MorphoSys (MOR), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry.
Wave Life Sciences vs.
Wave Life Sciences (NASDAQ:WVE) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.
Wave Life Sciences has a beta of -0.93, indicating that its share price is 193% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Wave Life Sciences has higher earnings, but lower revenue than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics has a net margin of -50.32% compared to Wave Life Sciences' net margin of -66.50%. PTC Therapeutics' return on equity of 0.00% beat Wave Life Sciences' return on equity.
PTC Therapeutics received 202 more outperform votes than Wave Life Sciences when rated by MarketBeat users. However, 67.84% of users gave Wave Life Sciences an outperform vote while only 61.92% of users gave PTC Therapeutics an outperform vote.
In the previous week, Wave Life Sciences had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 12 mentions for Wave Life Sciences and 10 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.98 beat Wave Life Sciences' score of 0.95 indicating that PTC Therapeutics is being referred to more favorably in the news media.
89.7% of Wave Life Sciences shares are held by institutional investors. 29.1% of Wave Life Sciences shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Wave Life Sciences currently has a consensus target price of $22.18, suggesting a potential upside of 262.45%. PTC Therapeutics has a consensus target price of $63.77, suggesting a potential upside of 32.33%. Given Wave Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Wave Life Sciences is more favorable than PTC Therapeutics.
Summary
Wave Life Sciences beats PTC Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 4/22/2025 by MarketBeat.com Staff
